Business Wire

OR-RADISYS

25.2.2022 18:02:10 CET | Business Wire | Press release

Share
Radisys Showcases Open Telecom and Digital Engagement Innovations at #MWC22

Radisys® Corporation , a global leader of open telecom solutions, today announced a showcase of its end-to-end open telecom and digital engagement portfolio at MWC Barcelona 2022 in Booth 5B81. Following the successful disaggregation of the flagship Media Server which is currently operating in over 200 networks, Radisys is extending the principles of disaggregation across both fixed and mobile broadband access offerings. Radisys’ Software-centric Network Functions, complemented by Open Hardware components, are now ready for operators to deploy to begin accruing the benefits of modern network architectures. Complementing these offerings, the focus on monetization leverages the power of computing-at-the-edge and offers new revenue opportunities.

Disaggregation of 5G and FTTX Access Networks

  • Radisys will demonstrate 5GNR solutions enabled with its Release 16 compliant 5G software and systems integration capabilities. Attendees will learn how Radisys with its ecosystem partners is enabling a diverse customer base in the 5G space for CSPs, private networks and other market verticals. The 5G Innovation Showcase will include a 5G Small Cell demonstration with highly optimized architecture and low footprint and a network-in-a-box demonstration with 5G vRAN protocol software.
  • Radisys will demonstrate its open, disaggregated, cloud native PON solution with the flexibility and scalability to transform FTTX networks. Attendees will see triple-play services over XGS-PON with Radisys’ Combo PON OLTs (simultaneous G-PON and XGS-PON support).
  • Radisys is actively participating in the SD-RAN and VOLTHA demonstrations with ONF. Meet Radisys at the ONF Pavilion Hall 1 (Booth 1F66).

Broadband-everywhere

  • Radisys will demonstrate the realization of true, converged broadband-everywhere networks powered by software-defined, disaggregated, Open RAN leveraging FTTX-based xHaul transport supported by automation, analytics monetization, and guaranteed assurance of service.
  • Radisys will showcase its complete network lifecycle services – consult, design, build, integrate, operate, and optimize – across all of the network domains of today’s digital networks including the RAN, Optical/IP Transport, Core and Enterprise networks.

Monetization

  • Radisys’ Smart Living Demonstration is made possible by Radisys’ Reach Smart Home that enables broadband service providers to increase customer stickiness and revenue by bundling smart home services with broadband plans. Use cases include comfort living, home security, safety and energy management. Radisys’ Smart Home Operator Dashboard brings insightful business KPIs for monetizing new services.
  • Radisys’ Digital Engagement showcase will highlight the video analytics capabilities of its Engage Platform, including mask detection and social distancing. Service providers can use these analytics to build specific applications such as biometric authentication and COVID policy enforcement.
    • Attendees will have a personalized interaction with Radisys’ Engage Video Assistant (EVA) – the world’s first three-in-one AI-based video bot.
    • Radisys will feature its newly launched Engage Digital Platform (EDP), a flexible, reliable and low code/no code Communications Platform-as-a-Service (CPaaS). Radisys will demonstrate the ease of use of the EDP Portal where admins and developers can create new services almost instantaneously via a drag and drop menu.

Leadership Presence

  • Radisys and global service providers Deutsche Telekom and Reliance Jio will share their joint vision on disaggregated access during an interactive panel discussion taking place Tuesday, March 1 at 15:10-15:25 CET on the DT booth stage, Booth 3M31.
  • Radisys is sponsoring the Open RAN Summit at MWC. Ganesh Shenbagaraman, head of integrated products and ecosystems, will participate on a panel discussion on “Open RAN Opportunity Use Cases” on March 2 from 2:30pm-3:30pm in CC3.13 Fira Gran Via.
  • Radisys’ head of Mobility Software and Services, Munish Chhabra will participate in Xilinx’s 5G Leadership Power Hour Theater Session on March 2 from 9:30am-11:00am at the CET Theater 2 in Hall 7.

“Our theme for MWC is ‘Connectivity Reimagined, Experience Reimagined, Telco Reimagined’ and we are showing service provider and enterprise customers how our solutions can aid their network and business transformation with open platforms and architectures, and new innovative services and digital engagement solutions to reimagine their role as true digital engagement providers,” said Natasha Tamaskar, head of Global Marketing, Business Strategy and Digital Endpoints Business, Radisys. “Unlike other modern OEMs in the market, Radisys has a unique position as our portfolio covers both fixed and mobile access and leverages the global footprint of our media platform complemented by digital endpoints and services. Our solutions enable greater service opportunities and enhanced digital experiences for customers across the globe.”

To meet with Radisys’ experts at MWC Barcelona and learn more about innovations in Open RAN, broadband, and digital engagement, contact open@radisys.com .

About Radisys

Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications’ and content providers’ complex deployment challenges. For more information, visit www.Radisys.com .

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye